“A new standard of care for elderly and fragile patients”

A BCL-2 inhibitor is convincing in new studies in the first-line treatment of AML patients who are not suitable for intensive chemotherapy [1]. Hematologists Dr. Georgios Georgiou and Prof. Photis Beris assess the impact of these new data on the existing therapeutic landscape.